Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:GMDANASDAQ:KLDONYSE:MDPNYSE:RCORNASDAQ:SLGL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMDAGamida Cell$0.02-8.2%$0.26$0.03▼$2.51$2.40M0.939.20 million shs2.20 million shsKLDOKaleido Biosciences$0.00$0.00$0.00▼$0.03$4K-0.064,361 shs935 shsMDPMeredith$58.78$18.00▼$59.16$2.70B2.07552,848 shs3.36 million shsRCORRenovacor$3.20$3.07$1.34▼$9.74$55.26M-0.2830,033 shsN/ASLGLSol-Gel Technologies$0.90+5.0%$1.05$0.79▼$4.20$25.08M1.3329,202 shs1,796 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMDAGamida Cell+14.09%-15.00%-95.41%-92.92%-98.99%KLDOKaleido Biosciences0.00%0.00%0.00%0.00%-50.00%MDPMeredith0.00%0.00%0.00%0.00%-20.00%RCORRenovacor0.00%0.00%0.00%0.00%0.00%SLGLSol-Gel Technologies-9.28%+1.40%-16.81%-24.17%-78.20%[Urgent!] Generational Wealth Gameplan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMDAGamida Cell0.5836 of 5 stars3.42.00.00.00.00.80.0KLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AMDPMeredithN/AN/AN/AN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/AN/AN/AN/ASLGLSol-Gel Technologies3.6454 of 5 stars3.85.00.00.03.31.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMDAGamida Cell2.75Moderate Buy$4.7530,348.72% UpsideKLDOKaleido BiosciencesN/AN/AN/AN/AMDPMeredithN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/ASLGLSol-Gel Technologies3.50Strong Buy$8.00788.79% UpsideCurrent Analyst RatingsLatest KLDO, RCOR, GMDA, SLGL, and MDP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails1/29/2024GMDAGamida CellJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMDAGamida Cell$1.78M1.35N/AN/A($0.02) per share-0.78KLDOKaleido Biosciences$1.10M0.00N/AN/AN/A∞MDPMeredith$2.98B0.00N/A5.68$14.27 per share0.00RCORRenovacorN/AN/AN/AN/A$2.47 per shareN/ASLGLSol-Gel Technologies$1.55M16.18N/AN/A$1.67 per share0.54Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMDAGamida Cell-$63M-$0.63N/A∞N/AN/AN/A-57.59%5/20/2024 (Estimated)KLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/AMDPMeredith$306.60M$5.9010.01N/AN/A9.66%41.72%4.92%N/ARCORRenovacor-$14.10M-$0.73N/AN/AN/AN/A-62.88%-48.90%N/ASLGLSol-Gel Technologies-$27.24M-$1.01N/AN/AN/A-1,331.01%-61.52%-53.75%5/10/2024 (Estimated)Latest KLDO, RCOR, GMDA, SLGL, and MDP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2024Q4 2023SLGLSol-Gel Technologies-$0.16-$0.17-$0.01-$0.17$0.27 million$0.45 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMDAGamida CellN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/AMDPMeredithN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMDAGamida Cell213.142.162.09KLDOKaleido BiosciencesN/AN/AN/AMDPMeredith4.031.391.36RCORRenovacorN/A6.606.60SLGLSol-Gel TechnologiesN/A9.109.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMDAGamida Cell50.34%KLDOKaleido Biosciences81.56%MDPMeredith78.23%RCORRenovacor45.84%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipGMDAGamida Cell3.40%KLDOKaleido Biosciences9.00%MDPMeredith9.79%RCORRenovacor14.40%SLGLSol-Gel Technologies66.51%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableKLDOKaleido Biosciences7642.62 million38.79 millionNot OptionableMDPMeredith5,33045.78 million41.30 millionOptionableRCORRenovacor1917.27 million14.78 millionNot OptionableSLGLSol-Gel Technologies3627.86 million9.33 millionOptionableKLDO, RCOR, GMDA, SLGL, and MDP HeadlinesSourceHeadlineSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 17.8% in Marchamericanbankingnews.com - April 15 at 5:40 AMSol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Creamglobenewswire.com - April 1 at 7:00 AMSol Gel Technologies Ltd (SLGL)investing.com - March 23 at 11:58 AMSLGL May 2024 2.500 putfinance.yahoo.com - March 16 at 1:25 PMSol-Gel Technologies: Q4 Earnings Insightsbenzinga.com - March 14 at 1:48 PMSol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 14 at 8:47 AMSol-Gel Technologies Ltd.: Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developmentsfinanznachrichten.de - March 14 at 3:47 AMSol-Gel Reports Full-Year 2023 Financial Results and Corporate Developmentsglobenewswire.com - March 13 at 7:00 AMSol-Gel Technologies Ltd. (SLGL) stock forecast and price targetfinance.yahoo.com - February 28 at 9:43 AMSol-Gel Technologies Stock (NASDAQ:SLGL), Quotes and News Summarybenzinga.com - February 22 at 10:05 AMOptimistic Buy Rating for Sol-Gel Technologies on Revolutionary Topical Treatment SGT-610’s Market Potentialmarkets.businessinsider.com - December 9 at 3:48 AMSol-Gel Technologies Ltd.: Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Studyfinanznachrichten.de - November 30 at 6:30 PMSol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Studyfinance.yahoo.com - November 30 at 8:29 AMSol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610finance.yahoo.com - November 28 at 9:36 AMIs Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?finance.yahoo.com - November 20 at 7:19 AMSol-Gel Technologies GAAP EPS of -$0.21 beats by $0.02, revenue of $0.21M misses by $0.48Mmsn.com - November 9 at 5:31 PMSol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 9 at 7:27 AMZacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologiesfinance.yahoo.com - October 31 at 9:35 AMIs Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Invest In Growth?finance.yahoo.com - October 10 at 10:05 AMSol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - August 30 at 2:55 PMHC Wainwright & Co. Maintains Sol-Gel Technologies (SLGL) Buy Recommendationmsn.com - August 15 at 5:07 AMExpert Ratings for Sol-Gel Technologiesmarkets.businessinsider.com - August 11 at 4:26 PMSol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimatesfinance.yahoo.com - August 10 at 2:04 PMSol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 10 at 9:03 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsGamida CellNASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.Kaleido BiosciencesNASDAQ:KLDOKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.MeredithNYSE:MDPMeredith Corp. engages in television broadcasting and magazine advertising business. It operates through the Local Media and National Media business segments. The Local Media segment includes television stations and offers websites, mobile-optimized websites, and mobile applications. The National Media segment consists of national consumer media brands delivered via multiple media platforms including print magazines and digital and mobile media, brand licensing activities, database-related activities, and business-to-business marketing products and services. The company was founded by Edwin Thomas Meredith in 1902 and is headquartered in Des Moines, IA.RenovacorNYSE:RCORRenovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.Sol-Gel TechnologiesNASDAQ:SLGLSol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.